XML 12 R4.htm IDEA: XBRL DOCUMENT v2.3.0.15
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data
3 Months Ended9 Months Ended184 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Revenues:     
Collaboration and research and development revenue   $ 100$ 3,100
Product revenue1641595244322,846
Grant revenue   163,648
Total revenue1641595245489,594
Operating expenses:     
Cost of goods sold95762733101,665
Research and development2,0661,4697,0054,968183,598
Selling, general and administrative2,0512,6125,8918,10387,857
Goodwill and intangibles impairment    7,934
Restructuring costs    2,634
Total operating expenses4,2124,15713,16913,381283,688
Operating loss(4,048)(3,998)(12,645)(12,833)(274,094)
Other income (expense):     
Costs associated with aborted 2004 IPO    (3,550)
Payment under guarantee    (1,652)
Change in valuation of derivative    (308)
Change in valuation of warrants44073643(443)6,713
Warrant re-pricing    (44)
Foreign exchange (losses)/gains28(25)(59)(63)(4,314)
Interest income97332413,713
Interest expense (7) (40)(4,677)
Total other income (expense)47748617(522)5,881
Loss before taxes(3,571)(3,950)(12,028)(13,355)(268,213)
Income tax benefit12614344350618,322
Net loss(3,445)(3,807)(11,585)(12,849)(249,891)
Dividends on preferred ordinary shares    (38,123)
Deemed dividend on convertible exchangeable preferred shares   (2,915)(3,515)
Dividend on convertible exchangeable preferred shares(182)(182)(546)(585)(3,475)
Net loss applicable to common shareholders$ (3,627)$ (3,989)$ (12,131)$ (16,349)$ (295,004)
Net loss per share- Basic and diluted$ (0.07)$ (0.11)$ (0.25)$ (0.47) 
Weighted average common shares outstanding53,711,67837,030,43648,981,74335,125,522